Pharma Stocks
-
Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13
NEW YORK, Jan 13, 2026, 14:32 (EST) — Regular session Shares of LGND dropped roughly 11% following the FDA’s decision…
Read More » -
Acadia sees $1.7B 2028 sales, pipeline updates
Key Terms phase 2 medical Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested…
Read More » -
Assessing UroGen Pharma (URGN) Valuation After ZUSDURI Secures Permanent J Code
UroGen Pharma (URGN) shares are in focus after the company reported that its bladder cancer therapy ZUSDURI now has a…
Read More » -
Insufficient Growth At NATCO Pharma Limited (NSE:NATCOPHARM) Hampers Share Price
When close to half the companies in India have price-to-earnings ratios (or “P/E’s”) above 25x, you may consider NATCO Pharma…
Read More » -
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 5.8% in the afternoon session after the company announced it had entered…
Read More » -
Is This Deep-Value Pharma Name Finally Near a Turning Poi
Bristol-Myers Squibb’s share price has been grinding lower, but fresh drug news, oncology milestones and a divided Wall Street are…
Read More » -
Tempus AI (TEM) Stock: Why Big Pharma Is Betting Big on This AI Platform
TLDR Tempus AI total contract value exceeded $1.1 billion, marking highest level in company history Company signed 70 data agreements…
Read More » -
Jenburkt Pharmaceuticals Downgraded to Sell Amid Technica…
Technical Trends Turn Bearish The primary catalyst for the downgrade lies in the technical analysis of Jenburkt Pharmaceuticals’ stock price…
Read More » -
Should NewAmsterdam’s Multi-Indication Obicetrapib Strategy Reshape How NAMS Investors View Pipeline Concentration?
NewAmsterdam Pharma recently outlined its late-stage plans for obicetrapib, including an expected EMA approval decision in the second half of…
Read More » -
Did COACH Trial Combo Data and FDA Priority Review Just Shift Ascendis Pharma’s (ASND) Investment Narrative?
Ascendis Pharma recently reported past Week 52 topline results from its Phase 2 COACH trial, showing that once-weekly TransCon CNP…
Read More »